Abstract: The present invention provides polynucleotides and polypeptides encoded thereby of human Type 2 RNase H. Methods of using these polynucleotides and polypeptides in enhancing antisense oligonucleotide therapies are also provided.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Inhibitor of DNA binding-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Inhibitor of DNA binding-1. Methods of using these compounds for modulation of Inhibitor of DNA binding-1 expression and for treatment of diseases associated with expression of Inhibitor of DNA binding-1 are provided.

Abstract: Disclosed is a composition comprising at least two synthetic, cooperative oligonucleotides, each comprising a region complementary to one of tandem, non-overlapping regions of a target single-stranded nucleic acid, and each further comprising a dimerization domain at a terminus of each of the oligonucleotides, the dimerization domains of the oligonucleotides being complementary to each other. Also disclosed are duplex structures, ternary complexes, pharmaceutical formulations, and methods utilizing the cooperative oligonucleotides of the invention.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Talin. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Talin. Methods of using these compounds for modulation of Talin expression and for treatment of diseases associated with expression of Talin are provided.

Abstract: The invention relates to the genetic manipulation of plants, particularly to the expression of hemoglobin genes in transformed plants. Nucleotide sequences for the hemoglobin genes and methods for their use are provided. The sequences find use in enhancing seed germination, seedling growth, and overall growth and metabolism of the plant.

Abstract: Antisense oligonucleotides useful for treating a disease state characterized by p53 induction, such as proliferative cell disorders, e.g. cancer, or a hypoxic state induced by an ischemic attack, such as stroke, are described. The antisense agents are preferably of the class known as “steric blocker” type oligonucleotides, including morpholino oligonucleotides, peptide nucleic acids, 2′-O-allyl or 2′-O-alkyl modified oligonucleotides, or N3′→P5′ phosphoramidate oligonucleotides.

Abstract: The present invention is related to an antisense-nucleic acid or effective derivatives thereof hybridizing with an area of the messenger RNA (mRNA) or the DNA, encoding the p185erbB-2 receptor (also termed c-erbB-2, HER2 or neu), a pharmaceutical composition, comprising an antisense nucleic acid or effective derivatives thereof hybridizing with an area of the messenger RNA (mRNA) or the DNA, encoding the c-erbB-2 receptor as well as the use of said antisense nucleic acids and derivatives thereof for the manufacturing of a pharmaceutical composition for the treatment of neoplasms and/or immune diseases and/or diseases involving pathological angiogenesis.

Abstract: The invention describes catalytic nucleic acid based compounds capable of cleaving nucleic acid polymers both in vivo and in vitro. Two embodiments of this invention are compounds with a short stem that does not base pair, a minizyme, and compounds with DNA hybridizing arms and RNA catalytic domain and stem, DNA-armed ribozymes. The compounds of this invention, while nucleotide based may be substituted or modified in the sugar, phosphate, or base. Methods of use and methods of treatment are also described.

Abstract: A method for conferring resistance to a parasite to a host of the parasite, which comprises isolating a gene fragment from the parasite and inserting the gene fragment or a DNA or RNA segment substantially homologous to the gene fragment or to a DNA or RNA sequence functionally equivalent to the gene fragment into the host, wherein (1) transcription of the gene fragment or the DNA or RNA segment in the host occurs in an anti-sense direction, (2) the gene fragment or the DNA or RNA segment is expressed as a gene product in the host, wherein the gene product is capable of disrupting an essential activity of the parasite, or (3) the gene fragment or the DNA or RNA segment is a binding site capable of competing with a native binding site in the parasite, is disclosed along with hosts produced by this process. Particularly preferred is conferring resistance using a gene fragment from a replicase gene of an RNA virus.

Abstract: The present invention provides a method for targeting a particular mRNA sequence in vivo by oral administration of a morpholino antisense compound having uncharged phosphorus-containing backbone linkages. Also disclosed is a non-invasive method of detecting and quantitating the in vivo presence of RNA containing one or more selected target sequences. The method includes administering to a subject a nuclease-resistant antisense oligomer which hybridizes by Watson-Crick base pairing to a region of the target RNA with a Tm substantially greater than 37° C. The oligomer is able to complex intracellularly with target RNA, and is released from intracellular sites as a nuclease-resistant heteroduplex, which can then be measured in a body fluid sample, e.g., urine.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of Lysophospholipase I. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding Lysophospholipase I. Methods of using these compounds for modulation of Lysophospholipase I expression and for treatment of diseases associated with expression of Lysophospholipase I are provided.

Abstract: The present invention provides rat connective tissue growth factor (CTGF), means for producing CTGF and therapeutic methods for using CTGF or derivatives therof. The invention further provides methods for modulating the activity of CTGF and methods for ameliorating a cell proliferative disorder associated with CTGF.

Abstract: A substantially pure protein that is a member of the apoptotic Ced-3/Ice cysteine protease gene family, Mch2&agr;, and an inactive isoform of it, Mch2&bgr;, are disclosed. Isolated nucleic acid molecules that encode Mch2&agr; and Mch2&bgr;, respectively, are disclosed. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier in combination with the protein or the nucleic acid molecules are disclosed. Fragments of nucleic acid molecules that encode Mch2&agr; and Mch2&bgr; having at least 10 nucleotides and oligonucleotide molecule comprising a nucleotide sequence complimentary to a nucleotide sequence of at least 10 nucleotides are disclosed. Recombinant expression vectors that comprise the nucleic acid molecule that encode Mch2&agr; or Mch2&bgr;, and host cells that comprise such recombinant vectors are disclosed. Antibodies that bind to an epitope on Mch2&agr; and/or Mch2&bgr; are disclosed. Methods of identifying inhibitors, activators and substrates of Mch2&agr; are disclosed.

Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of SRC-2. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding SRC-2. Methods of using these compounds for modulation of SRC-2 expression and for treatment of diseases associated with expression of SRC-2 are provided.

Abstract: The present invention provides oligonucleotides that hybridizes to a nucleic acid that encodes a fucosyltransferase (FUT). The fucosyltransferase is preferably FUT3 or FUT6, along with vectors that contain the same. Pharmaceutical formulations that contain such oligonucleotides or vectors are also provided, along with methods of use thereof in the treatment of cancer.

Abstract: A composition and method for enhancing paracellular transport across cell layers in an animal comprising an antisense oligonucleotide hybridizable with a region of the messenger RNA coding for the protein occludin which, when hybridized to the occludin mRNA, interferes with its translation such that occludin function is disrupted and paracellular permeability is increased across an epithelial cell layer or and endothelial cell layer in an animal.

Abstract: The invention features antisense oligonucleotide molecules that specifically bind polynucleotides encoding COX-2. The present invention provides antisense oligonucleotides capable of inhibiting COX-2 expression, and methods of use thereof to reduce activity of COX-2 in tissues in order to treat diseases such as, for example, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, chronic liver disease, ulcerative colitis, cell proliferative disorders, and inflammation associated with Alzheimer's Disease and stroke.

Abstract: The invention provides nucleic acid ligands to hepatocyte growth factor/scatter factor (HGF) and its receptor c-met. The nucleic acid ligands of the instant invention are isolated using the SELEX method. SELEX is an acronym for Systematic Evolution of Ligands by EXponential enrichment. The nucleic acid ligands of the invention are useful as diagnostic and therapeutic agents for diseases in which elevated HGF and c-met activity are causative factors.

Abstract: The present invention relates to a selection method that allows fast recovery and identification of functional gene fragments which selectively inhibit growth, e.g., are cytostatic or cytotoxic, of particular cell-types, such as transformed cells. The strategy relies, in part, on the ability of small gene fragments to encode dominant-acting synthetic genetic elements (SGEs), e.g., molecules which interfere with the function of genes from which they are derived. SGEs which can be identified by the subject method include, but are not limited to, inhibitory antisense RNA molecules, ribozymes, nucleic acid decoys, and small peptides.

Abstract: Compositions and methods are provided for the treatment and diagnosis of diseases associated with the expression of one or more of the &bgr;I, &bgr;II, &ggr;, &dgr;, &egr;, &zgr; or &eegr; isoforms (isozymes) of protein kinase C (PKC). Oligonucleotides are provided which are targeted to nucleic acids encoding PKC-&bgr;I, PKC-&bgr;II, PKC-&ggr;, PKC-&dgr;, PKC-&egr;, PKC-&zgr; or PKC-&eegr;. Provided herein are oligonucleotides specifically hybridizable with a translation initiation site, 5′-untranslated region, 3′-untranslated region or other targeted region of a &bgr;I, &bgr;II, &ggr;, &dgr;, &egr;, &zgr; or &eegr; isoform of PKC, wherein at least about 75% of the nucleoside units of a given oligonucleotide are joined together by a stereospecific (i.e., Sp or Rp) phosphorothioate 3′ to 5′ linkages. In preferred embodiments, the oligonucleotides of the disclosure additionally contain one or more chemical modifications.